Noah Labs develops AI-powered telemonitoring software for cardiology, with a flagship product called Noah Labs Ark that enables remote monitoring and management of chronic cardiovascular conditions. Ark integrates data from smartwatches, ECGs, and blood pressure monitors and was approved as a Class IIa medical device under the EU MDR in April. The company’s current clinical focus is heart failure, while the platform also monitors hypertension and cardiac arrhythmias. Noah Labs is researching AI voice-based diagnostics to detect changes in vocal tone caused by pulmonary edema and fluid accumulation, aiming to identify deterioration up to 14 days earlier than current methods. It has entered a strategic partnership with the German Heart Center of the Charité and is running clinical studies with partners including the Mayo Clinic. The company says its remote monitoring can enable earlier detection of risk and reduce cardiovascular complications, hospitalisations, and mortality. Noah Labs was founded in 2021 and is pursuing broader applications of its voice-analysis research for other medical conditions over the long term.

Total raised

$4M

Funding rounds

1

Latest round

Seed

Latest activity

Feb 2025